持续推荐景气度向上的创新药：恒瑞医药、华东医药、翰森制药、贝达药业、信立泰、科伦药业、百利天恒、荣 昌生物、科伦博泰生物、石药集团 推荐盈利增速拐点逐渐体现的CXO：药明生物、药明康德 看好创新器械国产替代：惠泰医疗 看好消费医疗复苏：爱尔眼科 【国泰海通医药团队】本周观点：继续推荐创新药、CXO等主线 【国泰海通医药团队】本周观点：继续推荐创新药、CXO等主线 持续推荐景气度向上的创新药：恒瑞医药、华东医药、翰森制药、贝达药业、信立泰、科伦药业、百利天恒、荣 昌生物、科伦博泰生物、石药集团 推荐盈利增速拐点逐渐体现的CXO：药明生物、药明康德 看好创新器械国产替代：惠泰医疗 ...

TTEC (TTEC) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Speaker0 Good morning and thank you for joining us today. 2025 is off to a good start with our financial performance exceeding plan. In the first quarter, our revenue was $534,000,000 which was in the range of our forecasted plan. EBITDA was $56,000,000 up from $55,000,000 in the prior year. This upside was driven by improved EBITDA margins of 10.6% versus 9.5% in the prior year. While we are pleased with our Q1 results, many of our clients are adop ...

AudioCodes (AUDC) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Speaker0 Please note this conference is being recorded. I will now turn the conference over to your host, Roger Chuchen, Investor Relations. Roger, the floor is yours. Speaker1 Thank you, operator. Hosting the call today are Shabtai Allisberg, President and Chief Executive Officer and Niran Baruch, Vice President of Finance and Chief Financial Officer. Before we begin, I'd like to remind you that the information provided during this call may c ...

本报告由华创证券有限责任公司编制 www.hczq.com 证券研究报告 | 医药生物 | 2025年5月4日 卖的出价或询价。本报告所载信息均为个人观点，并不构成对所涉及证券的个人投资建议。 请仔细阅读PPT后部分的分析师声明及免责声明。 华创医药投资观点&研究专题周周谈 · 第124期 医药行业2024年报及2025年一季报业绩综述 华创医药团队： 首席分析师 郑辰 联席首席分析师 刘浩 医疗器械组组长 李婵娟 中药和流通组组长 高初蕾 分析师 王宏雨 分析师 朱珂琛 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com 执业编号：S0360520120002 邮箱：liuhao@hcyjs.com 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com 执业编号：S0360524070007 邮箱：zhukechen@hcyjs.com @2021 华创 版权所有 第一 ...

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Views - The company's Q1 2025 revenue of 3.099 billion yuan represents a year-on-year growth of 16.03%, with a net profit attributable to shareholders of 306 million yuan, up 32.54% year-on-year [1][2]. - The report indicates that the company's revenue is in line with market expectations, and future performance is expected to show gradual quarter-on-quarter improvement [2]. - The company has adjusted its revenue forecasts for 2025-2027, with expected revenues of 14.077 billion yuan, 16.473 billion yuan, and 19.528 billion yuan, respectively [3]. Summary by Sections Financial Performance - In Q1 2025, the laboratory business generated 1.857 billion yuan in revenue, a 15.7% increase year-on-year, while the CMC business saw revenue of 693 million yuan, up 19.1% [2]. - The adjusted net profit for Q1 2025 was 349 million yuan, reflecting a 3.14% increase year-on-year [1][2]. - The gross margins for the laboratory and CMC businesses improved to 45.54% and 30.44%, respectively, with year-on-year increases of 140 basis points and 254 basis points [2]. Future Outlook - The company anticipates a continued upward trend in performance, supported by a rapid increase in new orders, which grew over 10% year-on-year in Q1 2025 [2]. - The company maintains its revenue guidance for 2025 at a growth rate of 10% to 15% [2]. Valuation and Earnings Forecast - The report adjusts the earnings per share (EPS) forecasts for 2025-2027 to 0.98 yuan, 1.22 yuan, and 1.54 yuan, respectively, with corresponding price-to-earnings (PE) ratios of 24, 19, and 15 times based on the closing price of 23.52 yuan per share on April 29, 2025 [3][8].

Investment Rating - The investment rating for the company is "Outperform" (maintained) [2] Core Insights - The company reported a strong recovery in Q1 2025, with revenue and profit both achieving double-digit growth. Q1 revenue reached 3.099 billion, a year-on-year increase of 16.03%, while net profit attributable to shareholders was 306 million, up 32.54% year-on-year [4][6] - All major business segments experienced growth, with laboratory services revenue at 1.857 billion (up 15.74% year-on-year) and a gross margin increase to 45.54%. CMC (small molecule CDMO) services revenue was 693 million (up 19.05% year-on-year) with a significant gross margin improvement to 30.44% [7] - The company is seeing strong growth from European clients, with revenue from North America and Europe increasing by 16.81% and 26.57% year-on-year, respectively. Revenue from global top 20 pharmaceutical companies grew by 29.05% year-on-year [7] - New orders are accelerating, with Q1 2025 new orders up over 10% year-on-year, and the company maintains its full-year guidance of 10%-15% revenue growth for 2025 [7] Financial Data and Profit Forecast - The company forecasts total revenue of 13.795 billion for 2025, with a year-on-year growth rate of 12.4%. The net profit attributable to shareholders is projected to be 1.819 billion, reflecting a growth rate of 1.4% [6][9] - The earnings per share (EPS) is expected to be 1.02 for 2025, with a gross margin forecasted to improve to 35.8% [6] - The return on equity (ROE) is projected to be 12.1% for 2025, with corresponding price-to-earnings (PE) ratios of 23, 20, and 17 for the years 2025, 2026, and 2027, respectively [6][7]

截至2025年4月29日 09:41，中证港股通医药卫生综合指数(930965)强势上涨1.66%，成分股药明康德 (02359)上涨5.07%，三生制药(01530)上涨4.41%，科伦博泰生物-B(06990)上涨4.10%，康方生物 (09926)，云顶新耀-B(01952)等个股跟涨。 港股医药ETF(159718)上涨1.84%，最新价报0.72元。拉长时间看，截至2025年4月28日，港股医药ETF 近1周累计上涨4.28%。 流动性方面，医疗创新ETF盘中换手0.23%，成交380.55万元。拉长时间看，截至4月28日，医疗创新 ETF近1月日均成交5236.46万元。 规模方面，医疗创新ETF最新规模达16.53亿元。 流动性方面，港股医药ETF盘中换手4.77%，成交1278.09万元。拉长时间看，截至4月28日，港股医药 ETF近1周日均成交1.52亿元。 规模方面，港股医药ETF近2周规模增长3903.52万元，实现显著增长，新增规模位居可比基金1/4。 份额方面，港股医药ETF近2周份额增长4600.00万份，实现显著增长，新增份额位居可比基金1/4。 消息面上，ASCO 会议召开在即 ...

智通财经APP获悉，国投证券发布研报称，根据Crunchbase的数据，2024年全球和美国创新药VC&PE投 融资金额分别同比增长1.93%和5.29%，2024年全球和美国创新药VC&PE投融资情况已恢复正增长，创 新药投融资环境已逐步改善；热门赛道研发方面，多肽、ADC等领域研发需求旺盛，推动相关领域研 发外包需求提升。目前CXO上市公司相关订单开始逐步改善且产能处于行业领先地位，看好CXO上市 公司业绩边际改善，其中，在订单方面，药明康德、药明合联、凯莱英、康龙化成、博腾股份等多家上 市公司新签/在手订单已及时回暖。 国投证券主要观点如下： 宏观维度：全球创新药投融资持续改善，研发需求复苏可期 根据Frost& Sullivan的数据，预计全球肽类药物的研发生产服务外包的市场规模从2025年的47亿美元增 长至2032年188亿美元，全球ADC药物的研发生产服务外包的市场规模有望从2022年的15亿美元增长至 2030年的110亿美元。 微观维度：新签订单及时回暖，看好2025年CXO业绩改善 目前CXO上市公司相关订单开始逐步改善且产能处于行业领先地位，看好CXO上市公司业绩边际改 善。其中，订单方 ...

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. EDT. The conference call can be accessed by dialing 1-800-343-4849 from the United States or 1-203-518-9848 int ...

CXO、维生素、电力等板块逆市走强。 今天上午A股市场整体窄幅震荡，电力、CXO、维生素等概念板块走强。 新股方面，今天A股市场有两只新股上市，悉数大幅上涨，其中新股江顺科技盘中涨幅一度超过120%。 港股市场盘中走低，不过仍有不少股票大涨，其中凯莱英港股盘中一度大涨超19%。 A股市场窄幅震荡 今天上午A股市场整体窄幅震荡走低。截至午间收盘，上证指数跌0.1%，深证成指跌0.66%，北证50指数跌2.8%，创业板 指跌0.68%。 主要行业板块和赛道方面，日用化工、煤炭、造纸、农林牧渔等板块涨幅居前。软件服务、互联网、矿物制品、IT设备 等板块跌幅居前。 电力板块走强，华银电力、西昌电力、郴电国际等多股涨停，另有多股大幅上涨。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 ▼ | | --- | --- | --- | --- | --- | | 600744 | 华银电力 | 3.85 | 0.35 | 10.00% | | 600505 | 西昌电力 | 17.31 | 1.57 | 9.97% | | 600969 | 郴电国际 | 8.07 | 0.73 | 9.95% | | 000601 ...